TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.

Nai-Jung Chiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.